Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 231
- Registration Number
- NCT07039916
- Locations
- ๐บ๐ธ
Site Number - 1010, Carlsbad, California, United States
๐บ๐ธSite Number - 1006, Clearwater, Florida, United States
๐บ๐ธSite Number - 1011, Yukon, Oklahoma, United States
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 162
- Registration Number
- NCT07032662
- Locations
- ๐บ๐ธ
Site Number - 1612, Tucson, Arizona, United States
๐บ๐ธSite Number - 1618, Carlsbad, California, United States
๐บ๐ธSite Number - 1619, Orange, California, United States
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 210
- Registration Number
- NCT07018323
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
- Conditions
- Primary Sjรถgren's Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 180
- Registration Number
- NCT06979531
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
- Conditions
- Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 56
- Registration Number
- NCT06980805
- Locations
- ๐บ๐ธ
Site Number - 1010, Anniston, Alabama, United States
๐บ๐ธSite Number - 1020, Birmingham, Alabama, United States
๐บ๐ธSite Number - 1018, San Diego, California, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 120
- Registration Number
- NCT06754462
- Locations
- ๐บ๐ธ
Site Number - 1008, Worcester, Massachusetts, United States
๐บ๐ธSite Number - 1021, Saint Clair Shores, Michigan, United States
๐บ๐ธSite Number - 1030, Kansas City, Missouri, United States
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 240
- Registration Number
- NCT06727604
- Locations
- ๐ต๐ท
Site Number - 1037, San Juan, Puerto Rico
๐ฌ๐งSite Number - 7002, Cardiff, United Kingdom
๐บ๐ธSite Number - 1036, Phoenix, Arizona, United States
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
- Conditions
- Graves Disease
- Interventions
- Drug: IMVT-1401 (batoclimab)
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 35
- Registration Number
- NCT05907668
- Locations
- ๐ฉ๐ช
Site Number - 6505, Mainz, Germany
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 277
- Registration Number
- NCT05581199
- Locations
- ๐บ๐ธ
Site Number - 1634, Los Angeles, California, United States
๐บ๐ธSite Number - 1603, Scottsdale, Arizona, United States
๐บ๐ธSite Number - 1618, Carlsbad, California, United States
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Immunovant Sciences GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT05524571
- Locations
- ๐น๐ท
Site Number - 4951, Istanbul, Turkey
๐บ๐ธSite Number -1520, Pasadena, California, United States
๐บ๐ธSite Number -1517, San Francisco, California, United States